Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Rezafungin (Rezzayo) vs Vosoritide (Voxzogo)
An educational, source-based comparison of Rezafungin (Rezzayo) and Vosoritide (Voxzogo) — how each peptide works, what it's researched for, and what to know before going deeper.
Once-weekly echinocandin for candidemia and invasive candidiasis.
Next-generation echinocandin structurally related to anidulafungin with enhanced stability, inhibiting β-(1,3)-D-glucan synthase; long half-life permits once-weekly IV dosing.
- Candidemia
- Invasive candidiasis
- • FDA-approved (2023).
- • Infusion reactions and photosensitivity reported.
C-type natriuretic peptide analog for achondroplasia.
Modified C-type natriuretic peptide (CNP) analog that binds NPR-B, antagonizing overactive FGFR3 signaling in the growth plate to increase endochondral bone growth in children with achondroplasia.
- Achondroplasia in children ≥5 years (now ≥4 months)
- • FDA-approved.
- • Transient blood pressure decrease; ensure adequate hydration/food before dosing.
Rezafungin (Rezzayo) vs Vosoritide (Voxzogo) — Key differences
- Class: Rezafungin (Rezzayo) is classified as Echinocandin · Antifungal, while Vosoritide (Voxzogo) is CNP Analog · Skeletal Growth.
- Primary research focus: Rezafungin (Rezzayo) — candidemia; Vosoritide (Voxzogo) — achondroplasia in children ≥5 years (now ≥4 months).
- Tag: FDA-Approved · Antifungal vs FDA-Approved · Genetic.